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The development of the proteasome inhibitor bortezomib is a prime example of successful bench-to-bedside research. NF-jB is
implicated in the pathogenesis of multiple myeloma (MM), and bortezomib blocks NF-jB activation and its sequelae. Additional
bortezomib mechanisms include interactions at the MM cell surface and mitochondrial level and in downstream apoptotic signaling.
In the pivotal bortezomib study, the response rate was 35%; time to progression (TTP), 7 months; and median duration of response,
14.3 months. Responses were associated with improvements in quality of life, increases in laboratory parameters, and decreased
transfusions. Bortezomib is thus indicated in the US for patients with relapsed, progressive MM and recommended for approval in
Europe. The conﬁrmatory phase III trial has been stopped early due to a signiﬁcant improvement in TTP with bortezomib. The
success of bortezomib in MM demonstrates the utility of targeting the tumour:host interaction and BM milieu, in addition to the
tumour itself.
 2004 Elsevier Ltd. All rights reserved.
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(VELCADE) in multiple myeloma (MM) is a wonderful
example of translational research. In 1994, Dharminder
Chauhan in our laboratory showed that the binding of
MM cells to bone marrow stromal cells (BMSCs) trig-
gered interleukin-6 (IL-6) transcription and secretion in
an NF-jB-dependent mechanism [1,2]. Others have
shown that NF-jB conferred drug resistance in MM
cells [3] and that adhesion molecules mediating binding
of MM cells to extracellular matrix proteins [4] and to
BMSCs was also NF-jB dependent [5].
Investigators discovered that proteasomes, multi-
subunit catalytic proteins with a 20S core symmetrically
bound to two 19S regulatory caps, are responsible for
the majority of protein degradation in cells. The pro-
teasome is part of the ubiquitin–proteasome pathway
which plays an essential role in the degradation of
proteins that are relevant to cancer initiation and pro-
gression including cell cycle regulators (p21, p27, and
cyclin E), pro- and anti-apoptosis factors (Bcl-2, Bax),* Tel.: +1-617-632-2144; fax: +1-617-632-2140.
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The ordered ubiquitination and degradation of these
proteins is required for the cell to progress through the
cell cycle and undergo mitosis. Inhibition of the pro-
teasome leads to cell cycle arrest in normal cells and
apoptosis in transformed cells. The proteasome inhibi-
tor bortezomib is a modiﬁed dipeptidyl boronic acid
that binds selectively and reversibly to the proteasome
and inhibits chymotryptic-like activity within the b ring
of the 26S proteasome. By inhibiting the proteasome,
bortezomib aﬀects multiple signaling pathways and the
antineoplastic activity involves inhibition of cell growth
and survival, induction of apoptosis, and inhibition of
expression of genes which control cellular adhesion,
migration, and angiogenesis.
One of these actions is the inhibition of NF-jB acti-
vation [6] (Fig. 1). Initially this was not pursued because
of concerns that inhibiting NF-jB would cause non-
speciﬁc toxicity. As the body of evidence on the speci-
ﬁcity of bortezomib in transformed cells and its ability
to induce apoptosis grew, Millennium Pharmaceuticals,
Inc. began phase I studies that showed bortezomib
was well tolerated and had early signs of anti-MM ac-
tivity; of the ﬁrst nine patients, one achieved a complete
Fig. 1. The inhibition of NF-jB activation.
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disease was achieved in eight patients [7].
In 1999 our laboratory conducted in vitro studies that
showed that bortezomib induced apoptosis even of
drug-resistant MM cell lines and patient cells and that it
overcame the resistance to conventional chemotherapy
conferred both by binding of MM cells to extracellular
matrix proteins and BMSCs, as well as by the related
induction and secretion of cytokines such as IL-6 [8]. We
then went on to show that bortezomib also inhibited
growth of human MM cells in a severe combined im-
mune deﬁciency (SCID) mouse model [9].
Very rapidly thereafter in 2001 Dr. Paul Richardson
in our center chaired a multicenter phase II trial of
bortezomib in refractory relapsed MM which showed
35% response rates (including 4% complete responses);
response duration of 14.3 months and survival of 17.8
months versus the 6–9 month expected survival; and
associated clinical beneﬁt including increased haemo-
globin levels and decreased transfusion requirements,
improved quality of life, stabilisation or improvement in
renal function, and improvement in suppressed normal
immunoglobulins [10]. On the basis of these results,
VELCADE was approved for use in the United States in
May 2003 and recently recommended for approval in
Europe for patients with MM who have received at least
2 prior therapies, with disease progression noted on the
last therapy.
A conﬁrmatory phase III study of VELCADE versus
high-dose dexamethasone in relapsed/refractory patients
recently completed accrual. Of note, in December 2003,the dexamethasone control arm was halted on the rec-
ommendation of the data safety monitoring committee
due to a signiﬁcant improvement in time to progression,
the primary endpoint, with VELCADE.
Gene microarray and proteomic analyses are both
determining targets of resistance and sensitivity to
bortezomib and providing the preclinical rationale for
clinical protocols combining bortezomib with conven-
tional and other novel therapies [11–13].
As noted above, the rationale for use of bortezomib
in MM was inhibition of NF-jB not only in the MM
cell but also in the BM milieu. Myeloma cells migrate
to the BM microenvironment and there bind to ex-
tracellular matrix proteins and BMSCs [14], which not
only localises them in the BM but also confers cell
adhesion-related drug resistance and triggers tran-
scription and secretion of cytokines [IL-6, vascular
endothelial growth factor (VEGF), insulin-like growth
factor-1 (IGF-1)] [2,15,16]. Both the expression of ad-
hesion molecules on MM cells and BMSCs as well as
the constitutive and MM binding triggered transcrip-
tion of these cytokines are modulated by NF-jB. In-
hibiting activation of NF-jB was therefore the original
rationale for use of the proteasome inhibitor bortezo-
mib. Speciﬁcally, NF-jB is constitutively in its inactive
state in the cytosol due to binding to IjB inhibitor
protein. This protein, as most intracellular proteins, is
ubiquitinated and then targeted for breakdown by the
proteasome. Once degraded, NF-jB can then translo-
cate to the nucleus, bind to the appropriate motif, and
induce transcription of target genes. Bortezomib blocks
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inactivated state.
Our studies have shown that bortezomib targets the
MM cell, the tumour cell–host interaction, and the BM
milieu. Speciﬁcally, bortezomib induces apoptosis of
drug resistant MM cell lines and patient cells, including
tumour cells resistant to alkylating agents, anthracy-
clines, and steroids [8]. In addition, it downregulates
expression of adhesion molecules on tumour cells and
BMSCs, thereby blocking adhesion of MM cells to BM
[5]. It inhibits both intrinsic and MM cell binding-
induced transcription and secretion of cytokines medi-
ating MM cell growth, survival, and drug resistance [8].
Finally it also inhibits angiogenesis.
Having shown in vitro ability of bortezomib to over-
come conventional drug resistance, we next tested its in
vivo activity against human MM cells in a SCID mouse
model [9]. Human MM cells were injected subcutane-
ously into SCIDmice which were then treated with either
saline control or bortezomib. Daily treatment with either
0.5 or 1.0 mg/kg drug signiﬁcantly reduced tumour vol-
ume and prolonged survival. In this model, biopsy of the
tumour revealed apoptosis and increased sub G0/G1
cells in the bortezomib-treated cohort compared to the
control saline treated animals in whom tumour remained
viable, with few apoptotic cells. Tumour-associated an-
giogenesis was also inhibited in this model.
Although the original premise for the use of bort-
ezomib in MM was inhibition of NF-jB, we have shown
that it has multiple other actions. First, we compared
the eﬀect of treatment with the speciﬁc NF-jB inhibitor,
IjB kinase inhibitor PS-1145, versus bortezomib on
MM cell growth [17]. The IjK inhibitor PS-1145 had
little, if any, eﬀect on MM cell proliferation, whereas
0.01 mM bortezomib markedly inhibited growth. This
suggests that bortezomib must be acting directly on MM
cells in ways other than NF-jB inhibition. Of note, PS-
1145 does inhibit the proliferation, of MM cells adher-
ent to BMSCs, as well as both the constitutive and MM
binding-induced transcription and secretion of IL-6.
We next examined eﬀects of bortezomib treatment of
MM cells at the levels of the cell surface, mitochondria,
and downstream caspase signaling cascades. Bortezomib
induces degradation of gp130, the J component of the
IL-6 receptor, at early time points while MM cells are
still viable, suggesting that part of the selectivity of this
agent for MM cells may be related to lack of respon-
siveness to IL-6 and associated growth, survival, and
drug resistance [18]. We have shown that bortezomib
treatment of MM cells triggers activation of JNK, with
release of proapoptotic second mitochondrial activator
of caspases (Smac) and cytochrome-c and activation of
downstream caspases [19]. It also induces generation
of reactive oxygenation species, with associated release
of Smac and cytochrome-c [20]. Finally and most im-
portantly, examining the pattern of triggering of apop-totic signaling cascades triggered by conventional and
novel therapies not only deﬁnes their mechanism of
action, but also provides the preclinical rationale for
combining novel agents with conventional agents or
each other in clinical treatment protocols [21]. For ex-
ample, one can combine agents which both trigger a
single cascade, i.e. Revimid and TRAIL inducing cas-
pase 8, or combine agents which trigger distinct cas-
cades, i.e. Revimid and bortezomib inducing caspase 8
and caspase 9 [22].
Finally we are utilizing gene microarray proﬁling and
proteomics both to deﬁne molecular targets of sensitiv-
ity and resistance to novel agents and to provide the
rationale for their clinical application. For example,
exposure of MM cells to bortezomib induces caspase,
downregulates survival, and upregulates heat shock
protein (hsp) stress response 90 transcripts [12]. This
data provided the rationale for exposing MM cells to
bortezomib and then blocking the induction of hsp90
with 17 AAG. A clinical trial of this combination will
begin soon, based upon the signiﬁcantly increased MM
cell cytotoxicity observed in vitro. Analysis of protein
expression reveals that bortezomib induces cleavage of
DNA repair kinases, i.e. DNA-PKcs, the ﬁrst evidence
that the proteasome inhibitor bortezomib inhibits DNA
repair [13]. Bortezomib can enhance sensitivity and
overcome resistance to DNA damaging agents in vitro,
and already early clinical experience suggests that ad-
dition of bortezomib can overcome clinical resistance to
melphalan and doxil. Therefore gene array and proteo-
mic analyses will allow for the rational clinical evalua-
tion of bortezomib together with conventional and other
novel therapies. Such application of translational re-
search to the clinic underscores the continued important
role of proteasome inhibitors in the treatment of mul-
tiple myeloma and ultimately, perhaps, across a broad
spectrum of malignancies.References
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